CHICAGO (AP) — CHICAGO (AP) — Xeris Biopharma Holdings, Inc. (XERS) on Tuesday reported a loss of $19.8 million in its second quarter.
On a per-share basis, the Chicago-based company said it had a loss of 14 cents.
The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 13 cents per share.
The company posted revenue of $38 million in the period, exceeding Street forecasts. Three analysts surveyed by Zacks expected $34.8 million.
Xeris Biopharma expects full-year revenue in the range of $145 million to $165 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XERS at https://www.zacks.com/ap/XERS
For copyright information, check with the distributor of this item, STATS Perform dba Automated Insights.
, source Associated Press News